Scotoma Reduction in AMD Patients Treated With Ranibizumab

Phase 1

Completed

• Conditions: Macular Degeneration

• Registration Number: NCT00467935
• Lead Sponsor: Retina Research Foundation

Brief Summary

This is a trial aimed at patients with advanced wet macular degeneration and macular scarring treated wiht intravitreal injections of Lucentis.

Detailed Description

Patients with severe wet macular degeneration and scarring in the center of the retina may benefit from treatment if the size of the blind spot is reduced wiht injections of Lucentis.

Study Timeline

• Study Start: 2007-03
• Study First Submitted: 2007-04-29
• Study First Submitted QC: 2007-04-30
• Study First Posted: 2007-05-01
• Primary Completion: 2007-11
• Study Completion: 2007-11
• Status Verified: 2011-07
• Last Update Submitted: 2011-07-28
• Last Update Posted: 2011-07-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• BCVA < 20/320
• Disciform macular degeneration wiht exudation

Exclusion Criteria

• Non-amd CNV

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
scotoma reduction	12 months

Secondary Outcome Measures

Name	Time	Method
improved visual function	12 months

Trial Locations

Locations (1)

Retina Research Center; 🇺🇸 Slingerlands, New York, United States